全文获取类型
| 收费全文 | 81082篇 |
| 免费 | 7545篇 |
| 国内免费 | 137篇 |
专业分类
| 耳鼻咽喉 | 963篇 |
| 儿科学 | 2450篇 |
| 妇产科学 | 2235篇 |
| 基础医学 | 11390篇 |
| 口腔科学 | 1476篇 |
| 临床医学 | 11321篇 |
| 内科学 | 15228篇 |
| 皮肤病学 | 1015篇 |
| 神经病学 | 7042篇 |
| 特种医学 | 2452篇 |
| 外国民族医学 | 2篇 |
| 外科学 | 10045篇 |
| 综合类 | 1296篇 |
| 一般理论 | 104篇 |
| 预防医学 | 9272篇 |
| 眼科学 | 1213篇 |
| 药学 | 5639篇 |
| 1篇 | |
| 中国医学 | 96篇 |
| 肿瘤学 | 5524篇 |
出版年
| 2022年 | 583篇 |
| 2021年 | 1571篇 |
| 2020年 | 963篇 |
| 2019年 | 1535篇 |
| 2018年 | 1805篇 |
| 2017年 | 1330篇 |
| 2016年 | 1499篇 |
| 2015年 | 1668篇 |
| 2014年 | 2384篇 |
| 2013年 | 3430篇 |
| 2012年 | 4881篇 |
| 2011年 | 5074篇 |
| 2010年 | 2760篇 |
| 2009年 | 2368篇 |
| 2008年 | 4335篇 |
| 2007年 | 4463篇 |
| 2006年 | 4394篇 |
| 2005年 | 4312篇 |
| 2004年 | 4038篇 |
| 2003年 | 3869篇 |
| 2002年 | 3716篇 |
| 2001年 | 1788篇 |
| 2000年 | 1750篇 |
| 1999年 | 1655篇 |
| 1998年 | 997篇 |
| 1997年 | 788篇 |
| 1996年 | 702篇 |
| 1995年 | 718篇 |
| 1994年 | 654篇 |
| 1993年 | 627篇 |
| 1992年 | 1269篇 |
| 1991年 | 1187篇 |
| 1990年 | 1140篇 |
| 1989年 | 1072篇 |
| 1988年 | 974篇 |
| 1987年 | 988篇 |
| 1986年 | 954篇 |
| 1985年 | 984篇 |
| 1984年 | 844篇 |
| 1983年 | 732篇 |
| 1982年 | 580篇 |
| 1981年 | 485篇 |
| 1980年 | 494篇 |
| 1979年 | 646篇 |
| 1978年 | 517篇 |
| 1977年 | 441篇 |
| 1976年 | 429篇 |
| 1974年 | 433篇 |
| 1973年 | 365篇 |
| 1972年 | 373篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
2.
3.
4.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
5.
6.
7.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献8.
9.
10.
Nancy C. Lee 《Public health reports (Washington, D.C. : 1974)》2015,130(2):121-Apr;130(2):121